KROHIGH SIGNALFINANCIAL10-K

KRO experienced a severe deterioration in operating cash flow generation alongside a substantial decline in profitability and cash position.

The company's operating cash flow collapsed to just $2.5M from $72.5M in the prior year, representing a near-complete erosion of cash generation capability. Combined with meaningfully reduced gross profit and a sharp decline in cash reserves from $106.7M to $33.2M, this suggests significant operational stress that could impact the company's ability to fund operations and growth investments.

Comparing 2026-03-09 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

KRO's financial position weakened considerably, with operating cash flow falling to minimal levels while gross profit declined substantially. The company's cash position dropped significantly to $33.2M while capital expenditures increased to $42.9M, creating a concerning gap between cash generation and investment needs. The reduction in current liabilities provided some offset, but the overall picture signals meaningful financial stress requiring close monitoring of liquidity and operational performance.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-96.6%
$72.5M$2.5M

Operating cash flow fell 96.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
-68.9%
$106.7M$33.2M

Cash declined 68.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Capital Expenditure
Cash Flow
+45.4%
$29.5M$42.9M

Capital expenditure jumped 45.4% — major investment cycle underway; assess returns on deployment.

Gross Profit
P&L
-40.7%
$359.3M$213.0M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Share Buybacks
Cash Flow
+26.1%
$2.3M$2.9M

Share repurchases increased 26.1% — management returning capital, signals confidence in intrinsic value.

Current Liabilities
Balance Sheet
-22.6%
$476.6M$368.8M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
+14.3%
$14.0M$16.0M

R&D investment increased 14.3% — signals commitment to future product development, though near-term margin impact.

Current Assets
Balance Sheet
-10%
$1.1B$994.5M

Current assets declined 10% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-06
ADDED
as of June 30, 2025 (the last business day of the Registrant s most recently-completed second fiscal quarter) approximated $ 134.6 million.
In 2025, we merged LPC into our wholly-owned subsidiary Kronos Louisiana, Inc.
We believe we are the largest TiO 2 producer and chloride process TiO 2 producer in Europe with 45% of our 2025 sales volumes attributable to markets in Europe.
We and our agents and distributors primarily sell our products in three major end-use markets: coatings, plastics and paper as well as into the market for white packaging inks.
Our TiO 2 is also included in engineering materials like polycarbonate or acrylonitrile butadiene styrene ( ABS ) which is used in the automotive industry and for appliances, consumer electronics and other applications.
+7 more — sign up free →
REMOVED
as of June 30, 2024 (the last business day of the Registrant s most recently-completed second fiscal quarter) approximated $ 272.2 million.
federal government on imports from Canada, where we have a manufacturing facility) Fluctuations in currency exchange rates (such as changes in the exchange rate between the U.S.
We believe we are the largest chloride process TiO 2 producer in Europe with 44% of our 2024 sales volumes attributable to markets in Europe.
We and our agents and distributors primarily sell our products in three major end-use markets: coatings, plastics and paper.
Manufacturing, operations and properties Manufacturing We produce TiO 2 in two crystalline forms: rutile and anatase.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →